Walleye Capital
JSPR icon

Walleye Capital’s Jasper Therapeutics JSPR Stock Holding History

Walleye Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,400
Closed -$19.2K – 5106
2023
Q2 		$19.2K Hold
1,400
– – ﹤0.01% 3809
2023
Q1 		$25.3K Buy
+1,400
New +$25.9K ﹤0.01% 3355

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Walleye Capital's JSPR Position: Q3 2024 in Review

Walleye Capital sold out of Jasper Therapeutics (JSPR) in Q3 2024, closing a stake of 52,669 shares — an estimated $1.2M sold.

Walleye Capital first reported a position in JSPR in Q3 2020 and held it in 5 quarters. The position peaked at $1.2M in Q2 2024. 81 funds tracked by Wall St. Rank hold JSPR as of Q3 2024.

  • Walleye Capital reported no remaining Jasper Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 52,669 Jasper Therapeutics shares in Q3 2024, an estimated $1.2M.
  • Walleye Capital first reported a position in Jasper Therapeutics in Q3 2020 and held it in 5 quarters.
  • Walleye Capital's Jasper Therapeutics position peaked at $1.2M in Q2 2024.
  • 81 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.